BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 32973088)

  • 1. Inferring transmission trees to guide targeting of interventions against visceral leishmaniasis and post-kala-azar dermal leishmaniasis.
    Chapman LAC; Spencer SEF; Pollington TM; Jewell CP; Mondal D; Alvar J; Hollingsworth TD; Cameron MM; Bern C; Medley GF
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25742-25750. PubMed ID: 32973088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India.
    Das VN; Pandey RN; Siddiqui NA; Chapman LA; Kumar V; Pandey K; Matlashewski G; Das P
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005196. PubMed ID: 27974858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
    Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent - A Systematic Literature Review.
    Hirve S; Boelaert M; Matlashewski G; Mondal D; Arana B; Kroeger A; Olliaro P
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004896. PubMed ID: 27490264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of asymptomatic Leishmania infection in Bangladesh by antibody and antigen diagnostic tools shows an association with post-kala-azar dermal leishmaniasis (PKDL) patients.
    Owen SI; Hossain F; Ghosh P; Chowdhury R; Hossain MS; Jewell C; Cruz I; Picado A; Mondal D; Adams ER
    Parasit Vectors; 2021 Feb; 14(1):111. PubMed ID: 33597000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
    Mondal D; Bern C; Ghosh D; Rashid M; Molina R; Chowdhury R; Nath R; Ghosh P; Chapman LAC; Alim A; Bilbe G; Alvar J
    Clin Infect Dis; 2019 Jul; 69(2):251-258. PubMed ID: 30357373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of a combined camp approach for vector control together with active case detection of visceral leishmaniasis, post kala-azar dermal leishmaniasis, tuberculosis, leprosy and malaria in Bangladesh, India and Nepal: an exploratory study.
    Banjara MR; Kroeger A; Huda MM; Kumar V; Gurung CK; Das ML; Rijal S; Das P; Mondal D
    Trans R Soc Trop Med Hyg; 2015 Jun; 109(6):408-15. PubMed ID: 25918216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh.
    Rahman KM; Islam S; Rahman MW; Kenah E; Ghalib CM; Zahid MM; Maguire J; Rahman M; Haque R; Luby SP; Bern C
    Clin Infect Dis; 2010 Jan; 50(1):73-6. PubMed ID: 19951168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased
    Cloots K; Marino P; Burza S; Gill N; Boelaert M; Hasker E
    Front Cell Infect Microbiol; 2021; 11():604117. PubMed ID: 33777831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Kala-Azar Dermal Leishmaniasis as a Reservoir for Visceral Leishmaniasis Transmission.
    Le Rutte EA; Zijlstra EE; de Vlas SJ
    Trends Parasitol; 2019 Aug; 35(8):590-592. PubMed ID: 31266711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
    Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.
    Islam S; Kenah E; Bhuiyan MA; Rahman KM; Goodhew B; Ghalib CM; Zahid MM; Ozaki M; Rahman MW; Haque R; Luby SP; Maguire JH; Martin D; Bern C
    Am J Trop Med Hyg; 2013 Aug; 89(2):345-53. PubMed ID: 23817330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential impact of human visceral leishmaniasis vaccines on population incidence.
    Le Rutte EA; Coffeng LE; Malvolti S; Kaye PM; de Vlas SJ
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008468. PubMed ID: 32614857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-kala-azar dermal leishmaniasis: does it play a role in the transmission of Leishmania donovani in the Sudan?
    El Hassan AM; Khalil EA
    Trop Med Int Health; 2001 Sep; 6(9):743-4. PubMed ID: 11555443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of sequelae of visceral leishmaniasis and their contribution to ongoing transmission of Leishmania donovani.
    Duthie MS; Goto Y; Ghosh P; Mondal D
    Pathog Dis; 2019 Aug; 77(6):. PubMed ID: 31589291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012.
    Desjeux P; Ghosh RS; Dhalaria P; Strub-Wourgaft N; Zijlstra EE
    Parasit Vectors; 2013 Jul; 6():196. PubMed ID: 23819611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.
    Das VN; Ranjan A; Pandey K; Singh D; Verma N; Das S; Lal CS; Sinha NK; Verma RB; Siddiqui NA; Das P
    Am J Trop Med Hyg; 2012 Jun; 86(6):959-61. PubMed ID: 22665600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
    Zijlstra EE
    Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.